#USA #Biopharma #Sen-Jam #Huntington, NY #Destum Partners

Sen-Jam Pharmaceutical Partners with Destum for Strategic Initiatives

Sen-Jam Pharmaceutical, a trailblazer in the biotech field focused on innovative anti-inflammatory solutions, has officially partnered with Destum Partners. This alliance, which aims to enhance Sen-Jam's strategic capabilities, focuses specifically on securing licensing and co-development opportunities for its lead products, SJP-001 and SJP-002C.

Aiming for Strategic Growth

The collaboration, initiated as of February 2025, is set to further Sen-Jam's mission of delivering effective treatments while maximizing shareholder value. This engagement includes a robust action plan that encompasses:

• - Identifying Potential Partners: The primary goal is to connect with key entities in Big Pharma, mid-sized biotech firms, and consumer health sectors.
• - Co-Development Ventures: By leveraging Destum Partners’ extensive industry network, Sen-Jam aims to expedite the commercialization process of their lead therapeutics.
• - M&A Opportunities: Exploring mergers and acquisitions may play a significant role in advancing the company's growth trajectory.
• - Structured Transaction Process: This involves various stages, such as outreach, due diligence, valuation modeling, term-sheet negotiations, and successful deal closure.

Investor Benefits with SJP-001

A notable aspect of this collaboration is its potential positive impact on the company's Fractional Royalty Rights (FRR) program associated with SJP-001. Investors involved in this initiative could benefit from potential licensing revenue, which may offer royalty revenues within 6-12 months post-licensing, aligning the financial success of investors with Sen-Jam's commercial achievements.

The Advantage of Destum Partners

With a robust history of over $5 billion in completed transactions, Destum Partners possesses unmatched expertise in pharmaceutical and healthcare deal-making. Their proficiency in strategic advisory services, transaction execution, and valuation modeling will be crucial for the success of the partnership.

Matt Vanderberg, the Managing Director at Destum Partners, expressed enthusiasm about this alliance, stating that Sen-Jam’s innovative therapies have the potential to transform patient care significantly. Their goal is to ensure the best partnerships are aligned to bring these groundbreaking therapeutics to market swiftly.

Looking Ahead to Strategic Milestones

The partnership has already kicked off with a formal transaction process. Key upcoming milestones include participation in significant biopharmaceutical events:

• - BIO-Europe Spring 2025 – Milan, March 2025
• - BIO International 2025 – Boston, June 2025
• - BIO-Europe Fall 2025 – Vienna, November 2025

These platforms will allow for meaningful discussions and negotiations with potential partners, making them vital to the partnership's success.

Commitment to Investor Value

Engaging Destum Partners firmly embraces Sen-Jam's commitment to enhancing long-term shareholder value by advancing SJP-001 and SJP-002C towards successful commercialization. This strategic collaboration is seen as the key to unlocking new revenue opportunities and asserting Sen-Jam's presence as a frontrunner in the anti-inflammatory therapeutic space.

Sen-Jam promises to keep its stakeholders informed as discussions advance and milestones are reached. Each step taken under the guidance of Destum Partners will solidify the company’s path toward achieving market success and offering significant returns to investors.

Jim Iversen, Co-Founder and CEO of Sen-Jam Pharmaceutical, expressed excitement about their progress, emphasizing their commitment to delivering impactful therapeutics that benefit both investors and the larger healthcare community.

About Sen-Jam Pharmaceutical

Dedicated to transforming inflammation treatment, Sen-Jam Pharmaceutical employs its Pleiotropic Anti-Inflammatory Remedies (PAIR) technology. This approach targets mast cell modulation to offer precise therapies that complement the body's immune systems while minimizing chronic inflammation's risks. For more information, visit wefunder.com/senjam.

About Destum Partners

Destum Partners specializes in advisory services for MA, licensing, and strategic partnerships in the life sciences domain. With vast experience in biopharma transactions, they help companies achieve transformative growth through effective strategic partnerships.